Ursodeoxycholic acid and chemoprevention of colorectal cancer

Gastroenterologie Clinique et Biologique

Volumn 34, Issue 10, 2010, Pages 516-522

  Serfaty, L ^a   Bissonnette, M ^b   Poupon, R ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; BILE ACID; CYCLOOXYGENASE 2; DEOXYCHOLIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; URSODEOXYCHOLIC ACID;

CANCER INHIBITION; CANCER RISK; CARCINOGENESIS; CHEMOPROPHYLAXIS; COLORECTAL ADENOMA; COLORECTAL CANCER; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERANCE; ENTERITIS; HUMAN; LIPID RAFT; NONHUMAN; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR PROMOTION;

ANTINEOPLASTIC AGENTS; CHEMOPREVENTION; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; EVIDENCE-BASED MEDICINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 77958458317     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2010.05.005     Document Type: Short Survey

References (70)

1. Bouvier A.M., Remontet L., Jougla E., Launoy G., Grosclaude P., Buemi A., et al. Incidence of gastrointestinal cancers in France. Gastroenterol Clin Biol 2004, 28:877-881.
2. Vogelstein B., Fearon E.R., Hamilton S.R., Kern S.E., Preisinger A.C., Leppert M., et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988, 319:525-532.
3. Giovannucci E., Egan K.M., Hunter D.J., Stampfer M.J., Colditz G.A., Willett W.C., et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995, 333:609-614.
4. Giovannucci E., Rimm E.B., Stampfer M.J., Colditz G.A., Ascherio A., Willett W.C. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994, 121:241-246.
5. Muscat J.E., Stellman S.D., Wynder E.L. Nonsteroidal anti-inflammatory drugs and colorectal cancer. Cancer 1994, 74:1847-1854.
6. Smalley W., Ray W.A., Daugherty J., Griffin M.R. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 1999, 159:161-166.
7. Thun M.J., Namboodiri M.M., Heath C.W. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991, 325:1593-1596.
8. Janne P.A., Mayer R.J. Chemoprevention of colorectal cancer. N Engl J Med 2000, 342:1960-1968.
9. Sandler R.S., Halabi S., Baron J.A., Budinger S., Paskett E., Keresztes R., et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003, 348:883-890.
10. Baron J.A., Cole B.F., Sandler R.S., Haile R.W., Ahnen D., Bresalier R., et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003, 348:891-899.
11. Benamouzig R., Deyra J., Martin A., Girard B., Jullian E., Piednoir B., et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003, 125:328-336.
12. Morvay K., Szentleleki K., Torok G., Pinter A., Borzsonyi M., Nawroth R. Effect of change of fecal bile acid excretion achieved by operative procedures on 1,2-dimethylhydralazine-induced colon cancer in rats. Dis Colon Rectum 1989, 32:860-863.
13. Cohen B.I., Raicht R.F., Deschner E.E., Takahashi M., Sarwal A.N., Fazzini E. Effect of cholic acid feeding on N-methyl-N-nitrosurea-induced colon tumors and cell kinetics in rats. J Natl Cancer Inst 1980, 64:573-578.
14. Hori T., Matsumoto K., Sakaitani Y., Sato M., Morotomi M. Effect of dietary deoxycholic acid and cholesterol on fecal steroid concentration and its impact on colonic crypt cell proliferation in azoxymethane-treated rats. Cancer Lett 1998, 124:7984.
15. Bayerdorffer E., Mannes G.A., Ochsenkuhn T., Dirschedl P., Wiebecke B., Paumgartner G. Unconjugated secondary bile acids in the serum of patients with colorectal adenomas. Gut 1995, 36:268-273.
16. Bayerdorffer E., Mannes G.A., Richter W.O., Ochsenkühn T., Wiebecke B., Köpcke W., et al. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology 1993, 104:145-151.
17. Costarelli V., Key T.J., Appleby P.N., Allen D.S., Fentiman I.S., Sanders T.A. A prospective study of serum bile acid concentrations and colorectal cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer 2002, 86:1741-1744.
18. Moorehead R.J., Campbell G.R., Donaldson J.D., McKelvey S.T. Relationship between duodenal bile acids and colorectal neoplasia. Gut 1987, 28:1454-1459.
19. Reddy B.S., Wynder E.L. Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps. Cancer 1977, 39:2533-2539.
20. Van der Werf S.D.J., Nagengast F.M., Van Berg Henegouwen G.P., Huijbregts A.W.N., Van Tongeren J.H.M. Colonic absorption of secondary bile acids in patients with adenomatous polyps and in matched controls. Lancet 1982, 1:759-762.
21. Meance S., Boutron-Ruault M.C., Myara A., Gerhardt M.F., Marteau P., Lavergne A., et al. Fecal primary bile acids and serum cholesterol are associated with colorectal adenomas. Dig Dis Sci 2003, 48:1751-1757.
22. Hill M.J., Melville D.M., Lennard-Jones J.E., Neale K., Ritchie J.K. Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis. Lancet 1987, 2:185-186.
23. Ochsenkuhn T., Bayerdorffer E., Meining A., Schinkel M., Thiede C., Nussler V., et al. Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer 1999, 85:1664-1669.
24. Stadler J., Yeung K.S., Furrer R., Marcon N., Himal H.S., Bruce W.R. Proliferative activity of rectal mucosa and soluble fecal bile acids in patients with normal colons and in patients with colonic polyps or cancer. Cancer Lett 1988, 38:315-320.
25. Poupon R., Poupon R.E. Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children. Pharmacol Ther 1995, 66:1-15.
26. Marteau P., Chazouilleres O., Myara A., Jian R., Rambaud J.C., Poupon R. Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenouus bile acids in man. Hepatology 1990, 12:1206-1208.
27. Earnest D.L., Holubec H., Wali R.K., Jolley C.S., Bissonette M., Bhattacharryya A.K., et al. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res 1994, 54:5071-5074.
28. Brasitus T.A. Primary chemoprevention strategies for colorectal cancer: ursodeoxycholic acid and other agents. Gastroenterology 1995, 109:2036-2039.
29. Serfaty L., De Leusse A., Rosmorduc O., Desaint B., Flejou J.F., Chazouilleres O., et al. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology 2003, 38:203-209.
30. Pardi D.S., Loftus E.V., Kremers W.K., Keach J., Lindor K.D. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124:889-893.
31. Tung B.Y., Emond M.J., Haggitt R.C., Bronner M.P., Kimmey M.B., Kowdley K.V., et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001, 134:89-95.
32. Alberts D.S., Martinez M.E., Hess L.M., Einspahr J.G., Green S.B., Bhattacharyya A.K., et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 2005, 97:846-853.
33. Thompson P.A., Wertheim B.C., Roe D.J., Ashbeck E.L., Jacobs E.T., Lance P., et al. Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients. Cancer Prev Res (Phila) 2009, 12:1023-1030.
34. Wali R.K., Stoiber D., Nguyen L., Hart J., Sitrin M.D., Brasitus T., et al. Ursodeoxycholic acid inhibits the initiation and postinitiation phases of azoxymethane-induced colonic tumor development. Cancer Epidemiol Biomarkers Prev 2002, 11:1316-1321.
35. Martinez J.D., Stratagoules E.D., LaRue J.M., Powell A.A., Gause P.R., Craven M.T., et al. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer 1998, 31:111-118.
36. Powell A.A., LaRue J.M., Batta A.K., Martinez J.D. Bile acid hydrophobicity is correlated with induction of apoptosis and/or growth arrest in HCT116 cells. Biochem J 2001, 356:481-486.
37. DeRubertis F.R., Craven P.A., Saito R. Bile salt stimulation of colonic epithelial proliferation. J Clin Invest 1984, 74:1614-1624.
38. Güldütuna S., Zimmer G., Imhof M., Bhatti S., You T., Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate. Gastroenterology 1993, 104:1736-1744.
39. Feldman R., Martinez J.D. Growth suppression by ursodeoxycholic acid involves caveolin-1 enhanced degradation of EGFR. Biochim Biophys Acta 2009, 1793:1387-1394.
40. Batta A.K., Salen G., Holubec H., Brasitus T.A., Alberts D., Earnest D.L. Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps. Cancer Res 1998, 58:1684-1687.
41. Heuman D.M., Bajaj R. Ursodeoxycholate conjugates protect against disruptions of cholesterol-rich membranes by bile salts. Gastroenterology 1994, 106:1333-1341.
42. Güldütuna S., Deisinger B., Weiss A., Freisleben H.J., Zimmer G., Sipos P., et al. Ursodeoxycholate stabilizes phospholipid-rich membranes and mimics the effect of cholesterol: investigations on large unilamellar vesicles. Biochim Biophys Acta 1997, 1326:265-274.
43. London E. Insights into lipid raft structure and formation from experiments in model membranes. Curr Opin Struct Biol 2002, 12:480-486.
44. Kawamata Y., Fujii R., Hosoya M., Harada M., Yoshida H., Miwa M., et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003, 278:9435-9440.
45. Hong J., Behar J., Wands J., Resnick M., Wang L.J., DeLellis R.A., et al. Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. Gut 2010, 59:170-180.
46. Handschin C., Meyer U.A. Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch Biochem Biophys 2005, 433:387-396.
47. Maran R.R., Thomas A., Roth M., Sheng Z., Esterly N., Pinson D., et al. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J Pharmacol Exp Ther 2009, 328:469-477.
48. Khare S., Chaudhary K., Bissonnette M., Carroll R. Aberrant crypt foci in colon cancer epidemiology. Methods Mol Biol 2009, 472:373-386.
49. Takayama T., Katsuki S., Takahashi Y., Ohi M., Nojiri S., Sakamaki S., et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998, 339:1277-1284.
50. Wali R.K., Khare S., Tretiakova M., Cohen G., Nguyen L., Hart J., et al. Ursodeoxycholic acid and F6-D3 inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin D1 and E-cadherin. Cancer Epidemiol Biomarkers Prev 2002, 11:1653-1662.
51. Khare S., Cerda S., Wali R.K., von Lintig F.C., Tretiakova M., Joseph L., et al. Ursodeoxycholic acid inhibits Ras mutations, wild-type Ras activation, and cyclooxygenase-2 expression in colon cancer. Cancer Res 2003, 63:3517-3523.
52. Khare S., Mustafi R., Cerda S., Yuan W., Jagadeeswaran S., Dougherty U., et al. Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38, and CCAAT/enhancer-binding protein. Nutr Cancer 2008, 60:389-400.
53. Hofman E.G., Ruonala M.O., Bader A.N., van den Heuvel D., Voortman J., Roovers R.C., et al. EGF induces coalescence of different lipid rafts. J Cell Sci 2008, 121:2519-2528.
54. Fichera A., Little N., Jagadeeswaran S., Dougherty U., Sehdev A., Mustafi R., et al. EGFR signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. Cancer Res 2007, 67:827-835.
55. Dougherty U., Sehdev A., Cerda S., Mustafi R., Little N., Yuan W., et al. Epidermal growth factor receptor controls flat dysplastic ACF development and colon cancer progression in the rat azoxymethane model. Clin Cancer Res 2008, 14:2253-2262.
56. Dougherty U., Cerasi D., Taylor I., Kocherginsky M., Tekin U., Badal S., et al. Epidermal growth factor receptor is required for colonic tumor promotion by dietary fat in the azoxymethane/dextran sulfate sodium model: roles of transforming growth factor and PTGS2. Clin Cancer Res 2009, 15:6780-6789.
57. Yasuda H., Hirata S., Inoue K., Mashima H., Ohnishi H., Yoshiba M. Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochem Biophys Res Commun 2007, 354:154-159.
58. Khare S., et al. Differential signaling pathways of tumor-promoting and tumor-inhibiting bile acids in colonic carcinogenesis. Falk Symp 2006, 149:129-145.
59. Khare S., Little N., Cerda S., Mustafi R., Kumar N., Moore C., et al. Chemopreventive ursodeoxycholic acid (UDCA) inhibits in vivo activation of ErbB2 and Ras by EGF in mouse colon. Gastroenterology 2004, 126:A26. [Abstract].
60. Khare S., Cohen G., Mustafi R., Cerda S., Wali R., Khare I., et al. Cholic acid and chemopreventive ursodeoxycholic acid cause opposing effects on Ras and Cox-2 in AOM tumorigenesis and human colon cancer cells. Gastroenterology 2004, 126:A504. [Abstract].
61. Im E., Martinez J.D. Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells. J Nutr 2004, 134:483-486.
62. Miura T., Ouchida R., Yoshikawa N., Okamoto K., Makino Y., Nakamura T., et al. Functional modulation of the glucocorticoid receptor and suppression of NF-kB-dependent transcription by ursodeoxycholic acid. J Biol Chem 2001, 276:47371-47378.
63. Ambs S., Merriam W.G., Bennett W.P., Felley-Bosco E., Ogunfusika M.O., Oser S.M., et al. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res 1998, 58:334-341.
64. Reddy B.S., Hirose Y., Lubet R., Steele V., Kelloff G., Paulson S., et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000, 60:293-297.
65. Bernstein C.N., Eaden J., Steinhart A.H., Munkholm P., Gordon P.H. Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. Inflamm Bowel Dis 2002, 8:356-361.
66. Narisawa T., Fukaura Y., Takeba N., Nakai K. Chemoprevention of N-methylnitrosourea-induced colon carcinogenesis by ursodeoxycholic acid-5-aminosalicylic acid conjugate in F344 rats. Jpn J Cancer Res 2002, 93:143-150.
67. Jacoby R.F., Cole C.E., Hawk E.T., Lubet R.A. Ursodeoxycholate/sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Gastroenterology 2004, 127:838-844.
68. Kohno H., Suzuki R., Yasui Y., Miyamoto S., Wakabayashi K., Tanaka T. Ursodeoxycholic acid versus sulfasalazine in colitis-related colon carcinogenesis in mice. Clin Cancer Res 2007, 13:2519-2525.
69. Baker D.E., Kane S. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis. Rev Gastroenterol Disord 2004, 4:86-91.
70. Asciutti S., Castellani D., Nardi E., Morelli O., Clementi M., Chistolini F., et al. A new amino acid derivative of ursodeoxycholate, (N-L-Glutamyl)-UDCA (UDCA-Glu), to selectively release UDCA in the colon. Anticancer Res 2009, 29:4971-4979.